Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Accounts Receivables · Q3 FY2026 · quarter ended Jan 2026
Accounts receivables grows, but more slowly than its trailing trend
Q3 FY2026 accounts receivables of $2.66M (cash outflow) rose 5.0% year over year, behind the +37.6% change in trailing-twelve-month accounts receivables. Sequentially, it rose 56.1% from the prior quarter.
Context
- Accounts receivables amounted to 14.7% of revenue in FY2025, up 7.5 pp from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.0% toward the trailing-twelve-month pace of +37.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (8.78M) USD
- Year-over-year change
- -339.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | (8.78M) | -339.3% |
| FY2024 | 2024-04-30 | (2M) | — |
| FY2023 | 2023-04-30 | 0 | — |
| FY2021 | 2021-04-30 | 0 | — |
| FY2020 | 2020-04-30 | 0 | — |
Accounts Receivables vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's LTM Jan 2026 accounts receivables of $8.99M is the 2nd largest of the 3 companies compared; the peer median is $54.34M.
- Its year-over-year change of +37.6% is the highest of 3, against a peer median of -36.6%.
- Accounts receivables amounts to 10.7% of revenue for KMTS, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $108.59M | +9.0% | +15.6% | 12.7% | |
| LTM Jan 2026 | $8.99M | +37.6% | — | 10.7% | |
| LTM Mar 2026 | $92K | -82.2% | -22.0% | 0.2% | |
| Peer median (excluding KMTS) | $54.34M | -36.6% | -3.2% | 6.4% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | (29.47M) | (34.1M) | (84.24M) | (94.12M) | (113.81M) |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M |
| Deferred Income Tax | 0 | 0 | (45K) | 12K | 64K |
| Stock-Based Compensation | 0 | 1.86M | 1.21M | 1.49M | 24.27M |
| Change in Working Capital | (2.01M) | (19K) | 1.3M | 4.39M | (6.2M) |
| Accounts Receivables | 0 | 0 | 0 | (2M) | (8.78M) |
| Inventory | 0 | 0 | (733K) | (1.18M) | (3.44M) |
| Accounts Payables | (790K) | (132K) | 2.14M | 7.34M | 2.84M |
| Other Working Capital | (1.22M) | 113K | (112K) | 223K | 3.18M |
| Other Non-Cash Items | 706K | 1.94M | 7.28M | 4.44M | 10.11M |
| Operating Cash Flow | (30.29M) | (29.9M) | (69.64M) | (72.24M) | (77.61M) |
| Capital Expenditures | (232K) | (336K) | (15.46M) | (12.51M) | (23.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 2K | 0 | 285K | 283K |
| Investing Cash Flow | (232K) | (334K) | (15.46M) | (12.23M) | (23.31M) |
| Debt Repayment | 0 | 20M | (5.33M) | 5.88M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 215.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (183K) | (187K) | (671K) | (799K) | (1.65M) |
| Other Financing Activities | 30.42M | 29M | 0 | (2.35M) | 12.73M |
| Financing Cash Flow | 30.24M | 48.82M | 96.11M | 77.73M | 330.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (286K) | 18.59M | 11M | (6.74M) | 229.35M |
| Free Cash Flow | (30.53M) | (30.23M) | (85.1M) | (84.75M) | (101.2M) |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.